We found that KMT2C and KMT2D mutations are relatively rare and mutually exclusive in newly diagnosed AML, with KMT2C mutations enriched in CEBPA‐mutated and KMT2D in NPM1‐mutated AML subtypes, respectively. This evidence concerns the gene CEBPA and acute myeloid leukemia.